Compare Bristol-Myers Squibb Co (BMY) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Direxion Daily TSLA Bull 2X Shares — how do they compare? Bristol-Myers Squibb Co trades at $63.85 (market cap $129.94B), while Direxion Daily TSLA Bull 2X Shares trades at $8. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while Direxion Daily TSLA Bull 2X Shares pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Direxion Daily TSLA Bull 2X Shares nearer its low. Which is the better fit depends on your goals.
| BMY | TSLL | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $65.89 | $23.03 |
52-Week Low | $42.60 | $6.74 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
TSLL, the Direxion Daily TSLA Bull 2X Shares ETF, is trading at $7.975, down 2.86% on the day, with a bearish technical signal from moving averages and oscillators showing neutral momentum. The ETF aims to deliver twice Tesla's daily returns, amplifying volatility in a stock known for significant price swings. Recent news highlights its sensitivity to Tesla's performance, with Q2 earnings on July 22, 2026, potentially driving sharp moves.
The outlook for TSLL is highly speculative, tied directly to Tesla's stock volatility, offering leveraged upside but with elevated risk of losses even in rising markets. Investors face risks from daily rebalancing decay, market sentiment shifts, and Tesla-specific developments, requiring caution due to the ETF's non-traditional structure and lack of fundamental company metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
